Results 41 to 50 of about 4,347,639 (355)

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

open access: yesFEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang   +2 more
wiley   +1 more source

p30 protein: a critical regulator of HTLV-1 viral latency and host immunity

open access: yesRetrovirology, 2019
The extraordinarily high prevalence of HTLV-1 subtype C (HTLV-1C) in some isolated indigenous communities in Oceania and the severity of the health conditions associated with the virus impress the great need for basic and translational research to ...
Ramona Moles   +8 more
doaj   +1 more source

Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy

open access: yesFEBS Letters, EarlyView.
The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley   +1 more source

Detecting horizontal gene transfer with metagenomics co-barcoding sequencing

open access: yesMicrobiology Spectrum
Horizontal gene transfer (HGT) is the process through which genetic information is transferred between different genomes and that played a crucial role in bacterial evolution.
Kai Han   +10 more
doaj   +1 more source

Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment

open access: yesFrontiers in Immunology, 2023
New York-esophageal cancer 1 (NY-ESO-1) belongs to the cancer testis antigen (CTA) family, and has been identified as one of the most immunogenic tumor-associated antigens (TAAs) among the family members.
Hong Zhou   +13 more
doaj   +1 more source

Unlocking the potential of cell‐permeable nanobodies for intracellular applications

open access: yesFEBS Letters, EarlyView.
This review outlines current strategies for delivery of nanobodies into cells and highlights recent examples of functional applications. By addressing and manipulating intracellular targets, these molecules hold great potential for treating cancer, respiratory diseases and neurological disorders, making this a vibrant area of research in the biomedical
Mariona Gené‐Verdés   +2 more
wiley   +1 more source

Cancer Vaccines

open access: yesThe Oncologist, 2002
AbstractLearning ObjectivesAfter completing this course, the reader will be able to: Explain the relationship between the tumor and host immune system.Recognize the mechanisms by which tumor cells escape the immune surveillance.Recognize the potential of vaccines in the treatment and prevention of cancer.Access and take the CME test online and receive ...
openaire   +2 more sources

Advances in Neoantigen-Based Cancer Vaccines. [PDF]

open access: yesCancers (Basel)
Neoantigen-based immunotherapies harness somatic mutations as tumor-specific targets and represent a major advance in personalized cancer treatment.
Wu AC, Nakamura Y, Kiyotani K.
europepmc   +2 more sources

Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor Cell

open access: yesAdvanced Science, 2023
Cancer immunotherapies have improved human health, and one among the important technologies for cancer immunotherapy is cancer vaccine. Antigens are the most important components in cancer vaccines.
Lu Diao, Mi Liu
doaj   +1 more source

Biomaterial-enhanced cancer vaccines

open access: yesMaterials & Design, 2022
Cancer vaccines are a promising strategy for preventing cancer progression through antitumor immunity activation. Some vaccines, such as Sipuleucel-T (an autologous active cellular immunotherapy), have been applied clinically.
Shengxian Li   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy